The coronavirus disease 2019 rebound study: a prospective cohort study to evaluate viral and symptom rebound differences in participants treated with nirmatrelvir …
Background The uptake of nirmatrelvir plus ritonavir (NPR) in patients with coronavirus
disease 2019 (COVID-19) has been limited by concerns around the rebound phenomenon …
disease 2019 (COVID-19) has been limited by concerns around the rebound phenomenon …
Incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir
Importance Some patients treated with nirmatrelvir-ritonavir have experienced rebound of
COVID-19 infections and symptoms; however, data are scarce on whether viral rebound …
COVID-19 infections and symptoms; however, data are scarce on whether viral rebound …
Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study
Background Viral rebound after nirmatrelvir–ritonavir treatment has implications for the
clinical management and isolation of patients with COVID-19. We evaluated an unselected …
clinical management and isolation of patients with COVID-19. We evaluated an unselected …
Rebound phenomenon after nirmatrelvir/ritonavir treatment of coronavirus disease 2019 (COVID-19) in high-risk persons
In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2
patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced …
patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced …
Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated …
SE Smith-Jeffcoat, JE Biddle, HK Talbot… - Clinical Infectious …, 2024 - academic.oup.com
Abstract Background Nirmatrelvir/ritonavir (N/R) reduces severe outcomes from coronavirus
disease 2019 (COVID-19); however, rebound after treatment has been reported. We …
disease 2019 (COVID-19); however, rebound after treatment has been reported. We …
[HTML][HTML] Viral and symptom rebound in untreated COVID-19 infection
Background: There are reports of viral RNA and symptom rebound in people with COVID-19
treated with nirmatrelvir/ritonavir. Since the natural course of viral and symptom trajectories …
treated with nirmatrelvir/ritonavir. Since the natural course of viral and symptom trajectories …
SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy: an observational study
GE Edelstein, J Boucau, R Uddin, C Marino… - Annals of Internal …, 2023 - acpjournals.org
Background: Data are conflicting regarding an association between treatment of acute
COVID-19 with nirmatrelvir− ritonavir (NR) and virologic rebound (VR). Objective: To …
COVID-19 with nirmatrelvir− ritonavir (NR) and virologic rebound (VR). Objective: To …
Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation
Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …
Clinical, virologic, and immunologic evaluation of symptomatic coronavirus disease 2019 rebound following nirmatrelvir/ritonavir treatment
Background Nirmatrelvir/ritonavir, the first severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) protease inhibitor, reduces the risk of hospitalization and death by …
(SARS-CoV-2) protease inhibitor, reduces the risk of hospitalization and death by …
Symptom and viral rebound in untreated SARS-CoV-2 infection
Background: Although symptom and viral rebound have been reported after nirmatrelvir–
ritonavir treatment, the trajectories of symptoms and viral load during the natural course of …
ritonavir treatment, the trajectories of symptoms and viral load during the natural course of …